Science Translational Medicine - A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity - 2023

Expert Opinion on Biological Therapy - Flow cytometry and receptor occupancy in immune-oncology - 2021

The Journal of Cellular and Molecular Medicine - The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3-ITD-Mutant Acute Myeloid Leukaemia - 2024

Cell Reports - Inhibition of Mutant IDH1 Promotes Cycling of Acute Myeloid Leukemia Stem Cells - 2022

In Vivo - Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML - 2022

Clinical Cancer Research - Translational Cancer Mechanisms & Therapy- AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells - 2020

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers - 2025

The Anti-FRα Antibody–Drug Conjugate Luveltamab  Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung  Cancer Preclinical Models and Induces Immunogenic Cell  Death - 2025

Current Protocols - Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoetic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents - 2020

Current Protocols - Development and Applications of Patient-Derived Xenograft Models in Humanized Mice for Oncology and Immune-Oncology Drug Discovery - 2020

Archives of Clinical and Biomedical Research - Pharmaco-Pheno-Multiomic Integration Reveal Biomarker Profiles and Therapeutic Response Prediction Models in Leukemia and Ovarian Cancer - 2023

Dual inhibition of HSF1 and DYRK2 impedes cancer progression - 2023

Frontiers in Drug Discovery - Artificial Intelligence Platform, RADR®, Aids in the Discovery of DNA Damaging Agent for the Ultra-rare Cancer Atypical Teratoid Rhabdoid Tumors - 2022

Frontiers in Oncology - Emerging Target Discovery and Drug Repurposing Opportunities in Chordoma - 2022

The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads

Identification and credentialing of patient-derived xenograft models of invasive lobular carcinoma - 2026

A novel potent and selective GCN2 inhibitor, APL-4098, has anti-leukemic activity through dysregulation of mitochondrial function Open Access - 2026

Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer - 2025

TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile

Molecular Cancer Therapeutics - The Anti-FRα Antibody-Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non-Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death - 2025

Molecular Cancer Therapeutics - Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors - 2025

Molecular Cancer Therapeutics - MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells - 2024

Molecular Cancer Therapeutics - Preclinical Characterization of XB002, an Anti-Tissue Factor Antibody-Drug Conjugate for the Treatment of Solid Tumors - 2024

Drug Discovery - Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers - 2024

Drug Discovery - A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation - 2024

Molecular Cancer Therapeutics - Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer - 2024

Nature Scientific Reports - Entinostat as a Combinatorial Therapeutic for Rhabdomyosarcoma - 2024

Nature - Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase - 2024

The Journal of Clinical Investigation - Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer - 2023

Cancer Research - The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance - 2023

Cancer Research Communications - PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Imrpove Response to PARP Inhibition and Chemotherapies - 2023

Journal for ImmunoTherapy of Cancer - INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses - 2023

Molecular Cancer Therapeutics - SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models - 2023

Cancer Discovery - Zenocutuzumab, a HER2xHer3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements - 2022

Molecular Cancer Therapeutics - DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-based Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Activities in Preclinical Models - 2022

Molecular Cancer Therapeutics - Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers - 2022

Journal of Medicinal Chemistry - Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer - 2021

Nature Communications - Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease - 2021

Cancer Cell - Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor - 2021

Clinical Cancer Research - The PSMA Targeting Half-Life Extended BiTE® Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer - 2021

Advanced Science News - Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling - 2021

American Association for Cancer Research - Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells - 2021

BMC Cancer - ABBV-176, a PRLR Antibody Drug Conjugate with a Potent DNA-Damaging PBD Cytotoxin and Enhanced Activity with PARP Inhibition - 2021

American Association for Cancer Research - 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer - 2021

Molecular Cancer Therapeutics - The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b - 2021

British Journal of Cancer - SLFN11 informs on standard of care and novel treatments in a wide range of cancer models - 2020

Clinical Cancer Research - OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models - 2020

Cell - Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids - 2020

Molecular Cancer Therapeutics - Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models - 2020

Molecular Cancer Therapeutics - ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine - 2020

Cells - Alternative Splicing of RAD6B and Not RAD6A Is Selectively Increased in Melanoma: Identification and Functional Characterization - 2019

Oncotarget - Volasertib preclinical activity in high-risk hepatoblastoma - 2019

Sci Signal - The HDAC3-SMARCA4-miR27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma - 2019

Breast Cancer Research - Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors - 2019

Oncogene - Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells - 2019

Nature Communications - AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity - 2019

Scientific Reports- Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer - 2019

Nature Communications - The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models - 2019

Cancer Research - PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models - 2017

Annals of Oncology - Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors - 2017

British Journal of Cancer - Comparative mutational landscape analysis of patient-derived tumour xenografts - 2017

Nature Communications - CX-5461 is a DNA G-Quadruplex Stabilizer with Selective Lethality in BRCA1/2 Deficient Tumours - 2017

PLOS One - Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma - 2016